- Home
- GNS vs LUNG Comparison
GNS vs LUNG Comparison
Compare GNS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- LUNG
- Stock Information
- Founded
- GNS 2002
- LUNG 1995
- Country
- GNS Singapore
- LUNG United States
- Employees
- GNS N/A
- LUNG N/A
- Industry
- GNS Other Consumer Services
- LUNG Industrial Specialties
- Sector
- GNS Real Estate
- LUNG Health Care
- Exchange
- GNS Nasdaq
- LUNG Nasdaq
- Market Cap
- GNS 81.8M
- LUNG 65.6M
- IPO Year
- GNS 2022
- LUNG 2020
- Fundamental
- Price
- GNS $0.91
- LUNG $1.72
- Analyst Decision
- GNS
- LUNG Buy
- Analyst Count
- GNS 0
- LUNG 7
- Target Price
- GNS N/A
- LUNG $7.66
- AVG Volume (30 Days)
- GNS 2.9M
- LUNG 317.4K
- Earning Date
- GNS 09-23-2025
- LUNG 10-29-2025
- Dividend Yield
- GNS N/A
- LUNG N/A
- EPS Growth
- GNS N/A
- LUNG N/A
- EPS
- GNS N/A
- LUNG N/A
- Revenue
- GNS $5,749,894.00
- LUNG $90,549,000.00
- Revenue This Year
- GNS $62.23
- LUNG $10.30
- Revenue Next Year
- GNS $69.63
- LUNG $14.72
- P/E Ratio
- GNS N/A
- LUNG N/A
- Revenue Growth
- GNS N/A
- LUNG 18.24
- 52 Week Low
- GNS $0.21
- LUNG $1.47
- 52 Week High
- GNS $1.92
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- GNS 47.97
- LUNG 47.63
- Support Level
- GNS $0.91
- LUNG $1.69
- Resistance Level
- GNS $1.04
- LUNG $1.94
- Average True Range (ATR)
- GNS 0.08
- LUNG 0.11
- MACD
- GNS 0.00
- LUNG 0.02
- Stochastic Oscillator
- GNS 31.48
- LUNG 41.65
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.